在医疗补助受益者中用于乙型肝炎的核胺类型的支出:2012-2021年
Stephen E Congly1, Mayur Brahmania2, Carla S Coffin3
1Divisions of Gastroenterology and Hepatology and Medical Transplant, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; O'Brien Institute of Public Health, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Annals of hepatology
|May 6, 2024
概括
在慢性乙型肝炎 (CHB) 治疗中,增加了通用核类相应物 (NA) 的使用,大大降低了药物开支. 政策转变有利于仿制药可以提高NA治疗计划的可持续性.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药物经济学 药物经济学
- 卫生政策 卫生政策
背景情况:
- 慢性乙型肝炎 (CHB) 管理依赖于核胺类同类 (NA),它们是有效但昂贵的.
- 纳的高成本对包括医疗补助在内的保险计划造成了巨大的财务负担.
更多相关视频
相关概念视频
02:27DNA Base Pairing
27.3K
Erwin Chargaff’s rules on DNA equivalence paved the way for the discovery of base pairing in DNA. Chargaff’s rules state that in a double-stranded DNA molecule,
27.3K
03:00Next-generation Sequencing
88.7K
The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
88.7K